PPT-Upfront Combination Therapy vs Step-Up Approach for PAH:

Program Themes Case 1 Case 1 Background and Diagnostics Case 1 Assessment Monotherapy vs Initial Combination Therapy AMBITION Trial PatientCentered Approach Clinical FollowUp of Patients With PAH. Pulmonary Arterial Hypertension (PAH). 2. Contents. Title. Slide. PAH explained. What is PAH?. 9. Changes in the pulmonary arteries in PAH. 10. Classification of PH. 11. How common is PAH?. 15. Why does PAH develop?. Dr Glen Clack. Senior Medical Director. Oncology Translational Medicine Unit. AstraZeneca . Challenges and Opportunities. 2. Author | 00 Month Year. Set area descriptor | Sub level 1. Barriers Perceived by Pharma. Athos Bousvaros MD, MPH. Advances in IBD Dec 2014. Disclosures (last 12 months). Consultant. Takeda/Millennium. Dyax. Cubist. Peabody Arnold (litigation). Research support. Prometheus. Questions. Should we use combination therapy in our pediatric IBD patients?. . . . . MIR imaging & . s. pectroscopy. ISM dust model & PAH. . vectorized. Monte Carlo model . SED of a clumpy AGN torus. Frank . Heymann. (PhD), Martin Haas, . Endrik. . Kr. Ya. . Gonna. Call. Pulm. Consults. Lana . Melendres. Pulm. /CC Division. Pulm. . Htn. Program Director. 4/24/13. Objectives. Define pulmonary hypertension (PH. ) and pulmonary arterial hypertension (PAH). Program Overview. PAH Diagnostic Tools . PAH: Importance of Early Diagnosis to Improve Patient Outcomes . Diagnostic Algorithm for PH. Echocardiographic Probability of PH in Symptomatic Patients With a Suspicion of PH. Identify patients at high risk for the development of PAH.. Utilize right heart catheterization to confirm the diagnosis of PAH.. Evaluate right ventricular function using screening tools and imaging tests.. Summer Institute – Sept. 11, 2011. Teachable Unit. Title: Proteins. Context. A one-week series in a 100-level course for biology majors given early in the semester. Class is 50-100 students. Learning Goals of Teachable Unit- . Case Study . Initial Presentation. Case Study. Medical History. Case Study. Physical Examination. Case Study. Test Results . Determinants of Prognosis in PAH. Risk Assessment in PAH. From the 2015 ESC/ERS Guidelines. Program Goals. Complementary Mechanism of Action . . DPP-4 Inhibitors SGLT2 Inhibitors . Clinical Pearls. Fixed-Dose Combination Therapies. Using Fixed-Dose Combination Therapies to Achieve HbA. 1c. Combination Code and Task Profile Procedures 1 This document is intended to assist you with the combination code load process and task profile additions. 2 Adding a New Combination Code Fill out the INF46 Spreadsheet (sample layout below). John Park, PGY1 . Hung IFN et al. ”Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: An open-label randomized, controlled, phase . PentacelTetanusDiphtheriaPertussis DTaPPolioIPVandHaemophilus influenzaetype b Hib Scleroderma-Spectrum Disorders. Dinesh Khanna, MD. Professor of Medicine,. Division of Rheumatology,. Department of Medicine. Director, Scleroderma Program. University of Michigan Medical Center. Ann Arbor, MI.